Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:04 AM
Ignite Modification Date:
2025-12-25 @ 4:04 AM
NCT ID:
NCT00184002
Eligibility Criteria:
Inclusion Criteria:
* Pathologic diagnosis of Non-Hodgkin's lymphoma of B-cell origin: follicular large cell, diffuse large cell (including all B-cell variants), Burkitt or Burkitt-like lymphoma
* All stages of disease
* Measurable or evaluable tumor parameter(s)
* Age greater than 17 years old
* Karnofsky performance status greater or equal to 50%
* AGC greater or equal to 1.0; platelets greater or equal to 75,000(unless abnormal because of lymphoma)
* Bilirubin less or equal to 2.0; SGOT less or equal to 3 times upper limit of normal (unless abnormal because of lymphoma)
* Creatinine less or equal to 2.0 or creatinine clearance greater or equal to 60 ml/min (unless abnormal because of lymphoma)
* LVEF greater or equal to 45%
* Concurrent RT with or without steroids for emergency conditions secondary to lymphoma (i.e., CNS tumor, cord compression)are permitted
* Men and women of childbearing potential must agree to use adequate birth control for the duration of the therapy and for 3 months after completion of therapy
* Signed informed consent
Exclusion Criteria:
* Prior systemic cytotoxic therapy or RT for lymphoma
* Second active tumor, other than non-melanomatous skin ca and in-situ cervical cancer
* HIV seropositive
* Primary CNS lymphoma
* Pregnant or nursing women
* Unable to comply with the requirements of the protocol, or unable to provide adequate informed consent, in the opinion of the PI
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00184002
Study Brief:
Protocol Section:
NCT00184002